Antithrombotic agents are the cornerstones of therapy for thrombosis. The compositions of
arterial and venous clots differ, rendering antiplatelet agents more effective for arterial …

Thromboembolic disorders are among the major causes of morbidity and mortality, and
anticoagulation remains the cornerstone of prevention and treatment of these disorders …

Until recently, warfarin had been one of the only treatment options for long-term
anticoagulation of patients with atrial fibrillation, venous thromboembolism, or other medical …

Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been
the mainstay of therapy for> 60 years, but both classes of agents have limitations. The “ideal” …

Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism,
is a cause of significant mortality and morbidity. For several decades, anticoagulant options …

The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level
monitoring are presently undergoing taut scrutiny for efficacies and potential side effects …

Anticoagulant drugs have an essential role in the prevention and treatment of
thromboembolic diseases. Currently available anticoagulants substantially reduce the …

Although their first application in clinical practice occurred in the 1940s, vitamin K
antagonists remain the only form of oral anticoagulant medication approved for long-term …

Dabigatran (a direct thrombin inhibitor) and rivaroxaban, apixaban, and edoxaban (direct
activated factor X inhibitors) are increasingly being used in clinical practice. Compared with …

Vitamin K antagonists are the mainstay in the prevention and treatment of thromboembolic
diseases. Although effective under optimal conditions, several drawbacks are imminent to …